 WOODCLIFF LAKE, N.J.--BUSINESS WIRE--Eagle Pharmaceuticals, Inc. Nasdaq: EGRX Eagle or the Company today announced financial results for the three and twelve months ended December 31, 2020, and reviewed key pipeline programs. Business and Recent Highlights: Posted strong year-over-year adjusted non-GAAP earnings growth of 36; Received a complete response letter CRL from U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for vasopressin. Ea 